Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
08 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
07 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics to Present at 2018 BIO CEO & Investor Conference
05 févr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
09 janv. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone...
Axsome Therapeutics to Present at Biotech Showcase 2018
19 déc. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
08 nov. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Upcoming Investor Conferences
18 sept. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017
07 sept. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2017 Financial Results
09 août 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...